Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nobelpharma Makes Global Debut with US Launch of Hyftor
September 1, 2022
- BMS, Nagoya University Tie Up for Innovative Drug Discovery
August 31, 2022
- Eisai Files New Injection Formulation of Fycompa in Japan
August 31, 2022
- Novo Seeks Japan Approval of Hemophilia Drug Concizumab
August 31, 2022
- Viatris Launches Japan PIII to Add GAD Indication for Effexor SR
August 31, 2022
- Taiho’s GIST Drug Jeselhy Now Available in Japan
August 31, 2022
- Daiichi Sankyo Files Vanflyta for Frontline AML in Japan
August 31, 2022
- Stelues Shipments to Get Back to Normal in September: Pfizer Japan
August 30, 2022
- Kymriah Now Approved for Follicular Lymphoma in Japan: Novartis
August 29, 2022
- Minomycin Supply Resumption to Be Delayed: Pfizer
August 26, 2022
- Pfizer Files Ritlecitinib for Alopecia Areata Treatment in Japan
August 26, 2022
- Meiji Pharma in Talks on Japan Rights to Arcturus’ COVID Jab Candidate
August 26, 2022
- Eisai, US Brain Health Diagnostics Provider Seal MOU to Boost Awareness, Development of Blood-Based Assays
August 25, 2022
- Sawai Breaks Ground on New Factory Building in Kyushu, Shipment Start Set for April 2024
August 24, 2022
- Sawai Chief Wants Expert Panel to Discuss Delisting of Generics Deemed No Longer Necessary
August 24, 2022
- Pfizer Continues to Halt Champix Shipments on Prolonged Fix of Manufacturing Process
August 24, 2022
- Takeda’s Dengue Vaccine Gets Its 1st Approval in Indonesia
August 24, 2022
- Daiichi Sankyo’s Quizartinib Accepted for European Review in 1st Line AML
August 24, 2022
- BMS Wants to Jolt Cancer Care Landscape with Broader I/O Combo Options, Pursuing LAG-3 Inhibitor in Japan Too
August 24, 2022
- All Companies Curbing Shipments of Meropenem, Top-Priority Drug Requiring Stable Supplies
August 23, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…